Quantcast

Latest 5-HT3 antagonist Stories

2009-05-14 09:44:22

Adding a third drug to a popular chemotherapy regimen can help reduce the nausea and vomiting that many patients experience.Researchers from the University of Vermont in Burlington, VT, studied 810 patients from 77 centers in 22 countries. The participants took the chemo regimen of dexamthesone and ondansetron. This is a treatment used for patients with many types of solid tumors including colorectal and pancreatic cancers. Some of the patients received a third drug -- casopitant mesylate...

2009-04-09 07:11:00

WARREN, N.J., April 9 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced the submission on April 7, 2009 of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the orally dissolving film strip (ODFS) formulation of ondansetron....

2009-04-09 07:00:00

Files NDA for Ondansetron Orally Dissolving Film Strip BioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF LAKE, N.J., April 9 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today provides an update on two of its pipeline products. Ondansetron Orally Dissolving Film Strip On April 7, 2009, Strativa submitted a New Drug Application (NDA) for its new orally dissolving film...

2009-03-20 06:00:00

ZURICH, Switzerland, March 20 /PRNewswire/ -- A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented today at the ESMO Symposium on Cancer and Nutrition in Zurich, Switzerland New data presented today at the ESMO (European Society of Medical Oncology) Symposium on Cancer...

2008-12-02 07:00:00

On Track to File NDA with FDA in Early to Mid-2009 WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its development partner, MonoSol Rx, reported the successful completion of all pivotal bioequivalence studies for a thin film formulation of ondansetron. The ondansetron thin film product is being developed for the prevention of chemotherapy-induced nausea...

2008-12-02 07:00:00

Expects to File NDA with FDA in Early to Mid-2009 WARREN, N.J., Dec. 2 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced the successful completion of all pivotal bioequivalence studies for a thin film formulation of ondansetron. The ondansetron thin film...

2008-11-05 12:00:30

ProStrakan Group, a specialty pharmaceutical company, has announced the US launch of Sancuso, its novel, patent protected, transdermal patch for the prevention of chemotherapy-induced nausea and vomiting in patients receiving chemotherapy. The company is also working with regulatory authorities to bring Sancuso to market in Europe. Sancuso was previously approved by the FDA as the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients...

2008-11-05 06:00:06

A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2008. The company also announced additional positive clinical data for its lead product, APF530, which has successfully completed a Phase 3 trial for the treatment of chemotherapy-induced nausea and vomiting (CINV). In addition, in order to better focus the company's resources on APF530 in light of current conditions in the capital markets, A.P....

2008-11-04 09:00:05

BEDMINSTER, N.J., Nov. 4 /PRNewswire-FirstCall/ -- ProStrakan Group plc today announced that SANCUSO(R) (Granisetron Transdermal System) is now available by prescription for patients with chemotherapy-induced nausea and vomiting (CINV) in the United States. Sancuso was approved by the U.S. Food and Drug Administration (F.D.A.) in September 2008 as the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or...

2008-11-03 09:00:40

A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced that Ronald J. Prentki, the Company's president and chief executive officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference, on Wednesday, November 12, 2008, at 10:20 a.m. Eastern time at The Palace Hotel in New York City. Interested parties can access a live audio webcast at www.appharma.com. An archived presentation will be available on the Company's Web site for 14 days....


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related